International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 1 , Pages 36-39 , 1 September 2009

Maximum vs. Mono Androgen Blockade and the Risk of Recurrence in Men With Localized Prostate Cancer Undergoing Brachytherapy

  • Ronald C. Chen, M.D., M.P.H.

      Affiliations

    • Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA
    • Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA
    • Corresponding Author InformationReprint requests to: Dr. Ronald C. Chen, Department of Radiation Oncology, Brigham & Women's Hospital, L-2, 75 Francis Street, Boston, MA 02445. Tel: (617) 278-0330; Fax: (617) 732-7347
    • ,
  • Natalia Sadetsky, M.D., M.P.H.

      Affiliations

    • Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group, UCSF Comprehensive Cancer Center, University of California, San Francisco, CA
    • ,
  • Ming-Hui Chen, Ph.D.

      Affiliations

    • Department of Statistics, University of Connecticut, Storrs, CT
    • ,
  • Peter R. Carroll, M.D.

      Affiliations

    • Department of Urology, Program in Urologic Oncology, Urology Outcomes Research Group, UCSF Comprehensive Cancer Center, University of California, San Francisco, CA
    • ,
  • Anthony V. D'Amico, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, MA

Received 22 August 2008 ,Revised 14 October 2008 ,Accepted 21 October 2008.

References 

  1. D'Amico AV, Chen MH, Renshaw AA, et al. Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial. JAMA. 2008;299:289
  2. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005;6:841
  3. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50:1243
  4. Laverdiere J, Nabid A, De Bedoya LD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004;171:1137
  5. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys. 2002;52:444
  6. Merrick GS, Butler WM, Wallner KE, et al. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:669
  7. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969
  8. Potters L, Torre T, Ashley R, et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol. 2000;18:1187
  9. D'Amico AV, Chen MH, Renshaw AA, et al. Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol. 2008;26:2979–2983
  10. D'Amico AV, Kantoff PW, Chen MH. Aspirin and hormone therapy for prostate cancer. N Engl J Med. 2007;357:2737
  11. Cooperberg MR, Broering JM, Litwin MS, et al. The contemporary management of prostate cancer in the United States: Lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171:1393
  12. Lubeck DP, Litwin MS, Henning JM, et al. The CaPSURE database: A methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 1996;48:773
  13. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457
  14. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965

 Previously presented in abstract form at the Genitourinary Cancers Symposium on February 15, 2008.

 Supported by TAP Pharmaceutical Products, Inc.

 Conflict of interest: none.

PII: S0360-3016(08)03741-3

doi: 10.1016/j.ijrobp.2008.10.059

International Journal of Radiation Oncology * Biology * Physics
Volume 75, Issue 1 , Pages 36-39 , 1 September 2009

Article Tools

* Image Usage & Resolution